Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2024
DOI: 10.1016/j.bbadis.2024.167447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024. Verfasst von Yuan Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China. Hauptthemen laut MEDLINE: Ferroptosis, Gefitinib, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which serves the critical pillar for the treatment of non-small cell lung cancer (NSCLC). However, the acquired resistance remains a challenge for its clinical application, for which, practical strategies to reverse gefitinib resistance in NSCLC are necessary. Ferroptosis, a programmed cell death driven by ferritin-dependent lipid peroxidation, involves in NSCLC progression and related chemoresistance. In our previous work, the self-synthesised EGFR inhibitor Yfq07 (N4, N6-disubstituted pyrimidine-4,6-diamine derivatives) displayed a considerable inhibitory effect on NSCLC both in vitro and in vivo. Herein, we observed that Yfq07 suppressed the proliferation of PC-9GR and HCC827GR cells, two gefitinib resistance NSCLC cell lines. Mechanically, Yfq07 inhibited the phosphorylation of the Discoidin Domain Receptor 1 (DDR1), a receptor tyrosine kinase (RTK) highly expressed in multiple cancers, accompanied by downregulated miR-3648 and upregulated SOCS2. Inhibition or knockdown of DDR1 suppressed the proliferation, migration, and invasion of gefitinib-resistant NSCLC cells, and on the other hand, also downregulated miR-3648 and promoted SOCS2 expression. More specifically, miR-3648 targeted the 3'UTR segment of SOCS2 mRNA and thus affecting the P-ERK signalling pathway to regulate the malignant behaviors of gefitinib-resistant NSCLC cells. Furthermore, Yfq07 also indirectly induced the ferroptosis of gefitinib-resistant NSCLC cells via SOCS2 triggered inhibition of xCT-GPX4 pathway. In conclusion, our study indicates that DDR1 inhibitor Yfq07 promotes ferroptosis and reverses gefitinib-resistance of NSCLC through DDR1-miR-3648-SOCS2 signalling pathway, which provides insights for targeted therapy of gefitinib-resistant NSCLC and drug developments targeting ferroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
- Department of Oral Implantology, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang, China.
- Department of Colorectal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
- Laocheng District, Luoyang Maternal and child health family planning service center, Laocheng, Luoyang, Henan 471000, China.
- School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
- School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China. Electronic address: wmcyh@wmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Qian, J., Fu, Y., Wang, Z., Hu, W., Zhang, J., Wang, Y., Guo, Y., Chen, W., Zhang, Y., Wang, X., Xie, Z., Ye, H., Ye, F., & Zuo, Z. (2024). Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2024.167447
Vancouver
Zhang Y, Qian J, Fu Y, Wang Z, Hu W, Zhang J, et al. Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024. doi:10.1016/j.bbadis.2024.167447
BibTeX
@article{Zhang2024,
author = {Zhang, Yuan and Qian, Jinheng and Fu, Yanneng and Wang, Zihan and Hu, Wanping and Zhang, Jinxia and Wang, Yuexuan and Guo, Yangyang and Chen, Weikang and Zhang, Yejun and Wang, Xuebao and Xie, Zixin and Ye, Hui and Ye, Faqing and Zuo, Zhigui},
title = {Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2024},
doi = {10.1016/j.bbadis.2024.167447}
}
EUVIMED